Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Mont...($188414 $144445 ...),Health

Date:11/5/2009

$188,414 $144,445 -------- -------- Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued expenses $9,509 $6,580 Accrued compensation 7,558 3,006 Income tax payable 95 - Deferred revenues 1,119 365 Deferred rent 301 241 --- --- Total current liabilities 18,582 10,192 Long-term deferred rent 1,766 1,955 Other long-term liabilities 300 79 Stockholders' equity: Preferred stock - - Common stock 17 17 Additional paid-in capital 155,476 143,616 Treasury stock (11) - Accumulated other comprehensive loss (354) (774) Accumulated earnings (deficit) 12,638 (10,640) ------ ------- Total stockholders' equity 167,766 132,219 ------- ------- Total liabilities and stockholders' equity $188,414 $144,445 -------- --------

                                     GENOPTIX, INC.
                     CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                       (unaudited)
                                     (in thousands)

                                          
'/>"/>
SOURCE  Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 
Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors